20 -7 (69) 2024 - Sh.A.Mustafaeva - NEPHROPATHIC COMORBIDITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

NEPHROPATHIC COMORBIDITY IN PATIENTS WITH RHEUMATOID ARTHRITIS

Sh.A.Mustafaeva - Bukhara State Medical Institute named after Abu Ali ibn Sina

Resume

This review is devoted to the incidence of chronic kidney disease in rheumatoid arthritis. Rheumatoid arthritis (RA) is a chronic inflammatory disease with predominant signs of inflammation and joint damage. According to research data from recent years, chronic kidney disease (CKD) in patients with RA is significantly more common than in patients without RA, and is closely associated with the risk of cardiovascular complications and high mortality. Determining the nature of renal damage requires correct interpretation of the clinical situation, the results of laboratory and instrumental research methods, as well as close interdisciplinary cooperation between a rheumatologist, nephrologist and clinical pathologist. Non-steroidal anti-inflammatory drugs (NSAIDs) are often used to relieve pain in patients with rheumatoid arthritis. In rheumatoid arthritis, the occurrence of chronic kidney disease depends, first of all, on the duration of the disease and the nature of the inflammatory process. The problem of kidney damage in rheumatoid arthritis is poorly understood and requires further research.

Keywords: rheumatoid arthritis; amyloidosis, nonsteroidal anti-inflammatory drugs, chronic kidney damage.

First page

121

Last page

127

For citation:Sh.A.Mustafaeva - NEPHROPATHIC COMORBIDITY IN PATIENTS WITH RHEUMATOID ARTHRITIS//New Day in Medicine 7(69)2024 121-127 https://newdayworldmedicine.com/en/new_day_medicine/7-69-2024

List of References

  1. Akhmadovna M. S. Reasons for the Development of Morphostructural Changes in Kidney Cells in Patients with Rheumatoid Arthritis //Vital Annex: International Journal of Novel Research in Advanced Sciences. 2022;1(5):396-401.
  2. Bianchi S., Bigazzi R., Campese V.M. Mikroalbuminuria in essential hypertension: significance, pathophisiology. And therapeutic implications //Am.J.Kidney Dis. 1999;34(5):973-995
  3. Cline DM. Chronic pain: evaluation and treatment in the emergency department. In: Greenfield RH, editor. Managing Pain and End-of-Life Issues. Atlanta: AHC Media LLC; 2007; P. 67-84.
  4. Dolgih S.V., Vorobieva O.A., Mazurov V.I. The specialties of the renal damage in connective tissue diseases and systemic vasculitis (literature review). Nefrologia. 2009;13(2):35-41. doi: 10.24884/1561-6274-2009-13-2-35-41
  5. Everaert K., Delenghe J.,Vande Wiel C. Uririnary alpha1-mikroglobulin detectsuropathy.A prospective study in 183 urological patients //clim.Chem.Lb.1998;36(5):309-315.
  6. Fede C., Conti G ., Cimenz R., Ricca M. N- acetyl-beta-D- glucosaminidase and beta 2 – microglobulin: prognostic markers in idiopathic nephrotik syndrome //J.Nephrol. 1999;12(1):51-55.
  7. Fiseha T, Tamir Z. Urinary markers of Tubular Injury in Early Diabetic Nephropathy. //Int J Nephrol 2016;2016:4647685. doi: 10.1155/2016/4647685
  8. Griffi M.R., Yared A., Waynea A.R. Non-steroidal anti-infl ammatory drugs and acute renal failure in elderly persons //Am. J. Ehidemiol. 2000;151(10):488-496.
  9. Henry D, Page J, Whyte I, et al. Consumption of non-steroidal anti-inflammatory drugs and the development of functional renal impairment in elderly subjects. Results of a case-control study. //Br J Clin Pharmacol. 1997 Jul;44(1):85-90.
  10. Hickson L.J., Crowson C.S., Gabriel S.E. et al. Development of reduced kidney function in rheumatoid arthritis. //Am J Kidney Dis. 2014;63:206-13. doi: 0.1053/j.ajkd.2013.08.010
  11. Hickson L.J., Crowson C.S., Gabriel S.E. Development of Reduced Kidney Function in Rheumatoid Arthritis. //Am J Kidney Dis 2014;63(2):206-213.
  12. Jonson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-infl ammatory drugs affect blood pressure? A meta-analysis //Ann. Intern. Med. 1994;121:289-300.
  13. Jonson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-infl ammatory drugs affect blood pressure? A meta-analysis //Ann. Intern. Med. 1994;121:289-300.
  14. Khan KN, Paulson SK, Verburg KM, et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. //Kidney Int. 2002 Apr;61(4): 1210-9.
  15. Khan KN, Paulson SK, Verburg KM, et al. Pharmacology of cyclooxygenase-2 inhibition in the kidney. //Kidney Int. 2002 Apr;61(4): 1210-9.
  16. Kholmurodovich U.F. Liver Fibrosis-Modern Methods of Diagnostics and Drug Correction //Central asian journal of medical and natural sciences. 2021;2(2)158-167.
  17. Kц mhoff M, Grone HJ, Klein T, et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. //Am J Physiol. 1997 Apr;272(4 Pt 2):F460-8.
  18. Lewis S.C., Langman M.L., Laporte J.R. et al. Dose-response relationships between individual nonaspirin nonsteroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient date //Br. J. Clin. Pharmacol. 2002;54:320-326;
  19. Lydford S., McKechnie K., Dougall I.Pharmacological studies on prostanoid receptors in the rabbit isolated saphenous vein: a comparison with the rabbit isolated ear artery //Br. J. Pharmcol. 1996;117:13-20.
  20. Morilend L. et al. Management of rheumatoid arthritis: the historical context //J. Rheumatol. 2001;286(6):1431-1452.

    file

    download